Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED90 of teglicarpidine fumarate + remimazolam vs sufentanil + remimazolam for analgesia in outpatient hysteroscopic surgery
ChiCTR2500112774Phase 4Not yet recruiting
- Sponsor
- Xiangyang Central Hospital
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of teglicarpidine (4 arms), sponsored by Xiangyang Central Hospital. Primary endpoint: ED90 of teglicarpidine fumarate + remimazolam for hysteroscopic surgery. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
teglicarpidine
Beyond the preview
Go deeper on ChiCTR2500112774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112774.